Skip to main content
SpringerLink
Log in

Ten things ICU specialists need to know about direct oral anticoagulants (DOACs)

  • What's New in Intensive Care
  • Published:
Intensive Care Medicine Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Hunt BJ (2014) Bleeding and coagulopathies in critical care. N Engl J Med 370:847–859

    Article  CAS  PubMed  Google Scholar 

  2. Lopez-Lopez JA, Sterne JAC, Thom HHZ, Higgins JPT, Hingorani AD, Okoli GN, Davies PA, Bodalia PN, Bryden PA, Welton NJ, Hollingworth W, Caldwell DM, Savovic J, Dias S, Salisbury C, Eaton D, Stephens-Boal A, Sofat R (2017) Oral anticoagulants for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis, and cost effectiveness analysis. BMJ 359:j5058

    Article  PubMed  PubMed Central  Google Scholar 

  3. Sterne JA, Bodalia PN, Bryden PA, Davies PA, Lopez-Lopez JA, Okoli GN, Thom HH, Caldwell DM, Dias S, Eaton D, Higgins JP, Hollingworth W, Salisbury C, Savovic J, Sofat R, Stephens-Boal A, Welton NJ, Hingorani AD (2017) Oral anticoagulants for primary prevention, treatment and secondary prevention of venous thromboembolic disease, and for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis and cost-effectiveness analysis. Health Technol Assess 21:1–386

    Article  PubMed  PubMed Central  Google Scholar 

  4. Tomaselli GF, Mahaffey KW, Cuker A, Dobesh PP, Doherty JU, Eikelboom JW, Florido R, Hucker W, Mehran R, Messe SR, Pollack CV Jr, Rodriguez F, Sarode R, Siegal D, Wiggins BS (2017) 2017 ACC expert consensus decision pathway on management of bleeding in patients on oral anticoagulants: a report of the American College of Cardiology Task Force on expert consensus decision pathways. J Am Coll Cardiol 70:3042–3067

    Article  PubMed  Google Scholar 

  5. Potze W, Arshad F, Adelmeijer J, Blokzijl H, van den Berg AP, Meijers JC, Porte RJ, Lisman T (2014) Differential in vitro inhibition of thrombin generation by anticoagulant drugs in plasma from patients with cirrhosis. PLoS One 9:e88390

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Lyons PG, Micek ST, Hampton N, Kollef MH (2018) Sepsis-associated coagulopathy severity predicts hospital mortality. Crit Care Med. https://doi.org/10.1097/CCM.0000000000002997

    Article  PubMed  PubMed Central  Google Scholar 

  7. Johansson PI, Stensballe J, Vindelov N, Perner A, Espersen K (2010) Hypocoagulability, as evaluated by thrombelastography, at admission to the ICU is associated with increased 30-day mortality. Blood Coagul Fibrinolysis 21:168–174

    Article  PubMed  Google Scholar 

  8. Jensen KOF, Hansen SH, Goetze JP, Jesting A, Stensballe J, Hansen H (2017) Preliminary report: measurement of apixaban and rivaroxaban in plasma from bleeding patients. Eur J Haematol 99:431–436

    Article  CAS  PubMed  Google Scholar 

  9. Solbeck S, Jensen AS, Maschmann C, Stensballe J, Ostrowski SR, Johansson PI (2018) The anticoagulant effect of therapeutic levels of dabigatran in atrial fibrillation evaluated by thrombelastography (TEG®), hemoclot thrombin inhibitor (HTI) assay and ecarin clotting time (ECT). Scand J Clin Lab Invest 78:25–30

    Article  CAS  PubMed  Google Scholar 

  10. Dias JD, Norem K, Doorneweerd DD, Thurer RL, Popovsky MA, Omert LA (2015) Use of thromboelastography (TEG) for detection of new oral anticoagulants. Arch Pathol Lab Med 139:665–673

    Article  CAS  PubMed  Google Scholar 

  11. Steffel J, Verhamme P, Potpara TS, Albaladejo P, Antz M, Desteghe L, Georg HK, Oldgren J, Reinecke H, Roldan-Schilling V, Rowell N, Sinnaeve P, Collins R, Camm AJ, Heidbuchel H (2018) The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: executive summary. Europace. https://doi.org/10.1093/europace/euy054

    Article  PubMed  Google Scholar 

  12. Marlu R, Hodaj E, Paris A, Albaladejo P, Crackowski JL, Pernod G (2012) Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban. A randomised crossover ex vivo study in healthy volunteers. Thromb Haemost 108:217–224

    Article  CAS  PubMed  Google Scholar 

  13. Pollack CV Jr, Reilly PA, van Ryn J, Eikelboom JW, Glund S, Bernstein RA, Dubiel R, Huisman MV, Hylek EM, Kam CW, Kamphuisen PW, Kreuzer J, Levy JH, Royle G, Sellke FW, Stangier J, Steiner T, Verhamme P, Wang B, Young L, Weitz JI (2017) Idarucizumab for dabigatran reversal - full cohort analysis. N Engl J Med 377:431–441

    Article  CAS  PubMed  Google Scholar 

  14. Wang X, Mondal S, Wang J, Tirucherai G, Zhang D, Boyd RA, Frost C (2014) Effect of activated charcoal on apixaban pharmacokinetics in healthy subjects. Am J Cardiovasc Drugs 14:147–154

    Article  CAS  PubMed  Google Scholar 

  15. Stangier J, Rathgen K, Stahle H, Mazur D (2010) Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study. Clin Pharmacokinet 49:259–268

    Article  CAS  PubMed  Google Scholar 

  16. Henry DA, Carless PA, Moxey AJ, O’Connell D, Stokes BJ, Fergusson DA, Ker K (2011) Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion. Cochrane Database Syst Rev 16(3):001886

    Google Scholar 

  17. Beitland S, Sandven I, Kjaervik LK, Sandset PM, Sunde K, Eken T (2015) Thromboprophylaxis with low molecular weight heparin versus unfractionated heparin in intensive care patients: a systematic review with meta-analysis and trial sequential analysis. Intensive Care Med 41:1209–1219

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Section for Transfusion Medicine, Capital Region Blood Bank, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark

    Jakob Stensballe

  2. Department of Anaesthesia, Centre of Head and Orthopaedics, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark

    Jakob Stensballe

  3. Department of Intensive Care 4131, Copenhagen University Hospital Rigshospitalet, Blegdamsvej 9, 2100, Copenhagen, Denmark

    Morten Hylander Møller

Authors
  1. Jakob Stensballe
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Morten Hylander Møller
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Morten Hylander Møller.

Ethics declarations

Conflicts of interest

Authors declare that they have no competing interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Stensballe, J., Møller, M.H. Ten things ICU specialists need to know about direct oral anticoagulants (DOACs). Intensive Care Med 45, 89–92 (2019). https://doi.org/10.1007/s00134-018-5192-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00134-018-5192-y

Keywords

Search

Navigation